MISSISSAUGA, ON, Aug. 21, 2012 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical
technologies company, today announced United States Food and Drug
Administration ("FDA") clearance of SurgiClear™ antimicrobial
silicone adhesive film dressing designed to cover and protect wound
sites and wound closure devices, as well as secure other primary
dressings to a patient's skin.
With its proven ability to kill over 99.99% of bacteria that
contact the wound dressings antimicrobial silicone adhesive and its
potential to prevent scarring, SurgiClear is a major advancement in
the treatment of wounds. Covalon's proprietary antimicrobial
silicone adhesive allows clinicians to monitor wounds through its
clear waterproof film so patients can resume normal activity
without fear of contamination or damage to a wound site.
"The FDA clearance of SurgiClear, the clearance of its sister
product IV Clear™ a few months ago, and very strong clinical
feedback received to date provides Covalon with all of the validity
necessary to license and sell both products," said Brian Pedlar, Covalon's Chief Executive Officer.
"Every year in the United States,
over 48 million in-patient procedures result in wounds that could
benefit from SurgiClear's antimicrobial silicone technology."
Like its recently cleared sister product IV Clear, Covalon's
SurgiClear antimicrobial film dressings for wounds have a number of
unique and highly desirable characteristics:
- SurgiClear combines the comfort of skin-friendly silicone
adhesive technology with the advanced antimicrobial protection of
two gold-standard antimicrobial agents - chlorhexidine and
silver.
- SurgiClear has uniquely bonded the two antimicrobials into the
actual adhesive of the soft and non-sensitizing silicone that
allows the clear film wound dressing to comfortably adhere to the
skin while providing antimicrobial protection.
- SurgiClear kills over 99.99% of bacteria that come into contact
with the dressing's antimicrobial adhesive and prevents the
re-growth of bacteria on patient's skin over 7 days of wear.
- SurgiClear is breathable unlike most other silicone
dressings.
- Patients are able to bathe while wearing the waterproof
silicone SurgiClear wound dressing.
- Studies have shown that SurgiClear is up to ten times less
painful on removal than leading film dressings that use acrylic
adhesives.
- Studies have shown that the use over a 14-day period of
silicone similar to SurgiClear prevents keloid and hypertrophic
scarring following surgical procedures.
SurgiClear is available for sale and/or license in the United States and Canada by contacting Covalon at
surgiclear@covalon.com or calling 1.877.711.6055.
About Covalon
Covalon Technologies Ltd. researches, develops and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.